Editorial: Antigenic Response to CT-P13 and Infliximab Originator in IBD Shows Similar Epitope Recognition-Evidence From Basic Science Supports Safe Switching to Biosimilars. Authors’ Reply

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14860
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Editorial: Suicide and IBD-a Call to Action. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

RMD Open
RheumatologyAllergyImmunology
2017English

Editorial: Which Iron Preparation for Patients With IBD? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Social Supports: The Authors Reply

Health Affairs
MedicineHealth Policy
2013English

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

2018English

Editorial: Volatile Organic Compounds in Breath for Monitoring IBD-longitudinal Studies Are Essential. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy